Device-related epistaxis risk: continuous-flow left ventricular assist device-supported patients

Abstract

Background

The aim of this study was to analyze the effect of device-dependent factors on epistaxis episodes comparing patients supported with a continuous-flow left ventricular assist device (CF-LVAD) to patients under the same antithrombotic therapy.

Methods

Patients who underwent CF-LVAD between 2012 and 2018 were reviewed retrospectively from the institutionally adopted electronic database. Patients who underwent mitral valve replacement (MVR) surgery receiving the same anticoagulant and antiaggregant therapy were included as a control group. Demographics, epistaxis episodes, and nonepistaxis bleeding between the two groups were compared.

Results

A total of 179 patients met the inclusion criteria (61 patients CF-LVAD group, 118 patients MVR group). The median (range) follow-up periods for the study (CF-LVAD) and control (MVR) groups were 370 (2819) and 545.70 (2356) days, respectively. There was a significant difference for frequency of bleeding episodes per month between CF-LVAD and MVR groups (p = 0.003 < 0.05). The most common site of bleeding was the anterior septum in both groups (90.9% for the CF-MVR group and 100% for the MVR group). While 14 patients (23%) had nonepistaxis bleeding in the CF-LVAD group, only two patients (1.7%) had nonepistaxis bleeding in the MVR group. There were significant differences in nonepistaxis bleeding rates between the CF-LVAD and MVR groups (χ2=19.79, p < 0.001).

Conclusion

Both epistaxis and nonepistaxis bleeding rates were higher in the CF-LVAD group than in the MVR group. This suggests that the use of CF-LVAD support could directly increase the risk of hemorrhagic complications.

Level of evidence

2A (Etiology/Harm)

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. 1.

    Raj A, Wadhwa V, Jain A (2019) Epidemiological profile of ent emergencies: our experience. Indian J Otolaryngol Head Neck Surg 71:301–304

    Article  Google Scholar 

  2. 2.

    Beck R, Sorge M, Schneider A, Dietz A (2018) Current approaches to epistaxis treatment in primary and secondary care. Dtsch Arztebl Int 115(1–02):12–22

    PubMed  PubMed Central  Google Scholar 

  3. 3.

    Traboulsi H, Alam E, Hadi U (2015) Changing trends in the management of epistaxis. Int J Otolaryngol 2015:263987

    Article  Google Scholar 

  4. 4.

    Marin E, Watelet J, Gevaert P et al (2019) Severe spontaneous epistaxis: retrospective study in a tertiary ENT centre. Eur Arch Otorhinolaryngol 276:1693–1699

    Article  Google Scholar 

  5. 5.

    Buchberger AMS, Baumann A, Johnson F et al (2018) The role of oral anticoagulants in epistaxis. Eur Arch Otorhinolaryngol 275:2035–2043

    CAS  Article  Google Scholar 

  6. 6.

    Hollowell J, Ruigómez A, Johansson S, Wallander MA, García- Rodríguez LA (2003) The incidence of bleeding complications associated with warfarin treatment in general practice in the United Kingdom. Brit J Gen Pract 53(489):312–314

    Google Scholar 

  7. 7.

    Najjar SS, Slaughter MS, Pagani FD et al (2014) An analysis of pump thrombus events in patients in the HeartWare advance bridge to transplant and continued access protocol trial. J Heart Lung Transplant 33(1):23–34

    Article  Google Scholar 

  8. 8.

    Frazier OH, Rose EA, McCarthy P et al (1995) Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg 222(3):327–338

    CAS  Article  Google Scholar 

  9. 9.

    Rose EA, Gelijns AC, Moskowitz AJ et al (2001) Randomized evaluation of mechanical assistance for the treatment of congestive heart failure (REMATCH) study group. Long- term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 345(20):1435–1443

    CAS  Article  Google Scholar 

  10. 10.

    Crow S, John R, Boyle A et al (2009) Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 137(1):208–215

    CAS  Article  Google Scholar 

  11. 11.

    Genovese EA, Dew MA, Teuteberg JJ et al (2009) Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation. Ann Thorac Surg 88(4):1162–1170

    Article  Google Scholar 

  12. 12.

    Pagani FD, Miller LW, Russell SD et al (2009) HeartMate II investigators extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol. 54(4):312–321

    Article  Google Scholar 

  13. 13.

    Kirklin JK, Naftel DC, Kormos RL et al (2011) Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant 30(2):115–123

    Article  Google Scholar 

  14. 14.

    Patel SR, Vukelic S, Jorde UP (2016) Bleeding in continuous flow left ventricular assist device recipients: an acquired vasculopathy? J Thorac Dis 8(10):E1321–E1327

    Article  Google Scholar 

  15. 15.

    Susen S, Rauch A, Van Belle E, Vincentelli A, Lenting PJ (2015) Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis. J Thromb Haemost 13(10):1757–1767

    CAS  Article  Google Scholar 

  16. 16.

    Fiore M, James C, Mouton C, Calderon J, Barandon L, Ouattara A, Picard F (2014) Assessment of platelet function with light transmission aggregometry in 24 patients supported with a continuous- flow left ventricular assist device: a single-center experience. J Thorac Cardiovasc Surg 148:3119–3125

    Article  Google Scholar 

  17. 17.

    Fressinaud E, Meyer D (1993) International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost 70:546

    CAS  Article  Google Scholar 

  18. 18.

    Meyer AL, Malehsa D, Budde U, Bara C, Haverich A, Strueber M (2014) Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail 2(2):141–145

    Article  Google Scholar 

  19. 19.

    Crow S, Chen D, Milano C et al (2010) Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg 90(4):1263–1269

    Article  Google Scholar 

  20. 20.

    Uriel N, Pak SW, Jorde UP et al (2010) Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 56(15):1207–1213

    Article  Google Scholar 

  21. 21.

    Brown CS, Hachem R, Jang DW (2018) Management of epistaxis in patients with ventricular assist device: a retrospective review. J Otolaryngol Head Neck Surg 47(1):48

    Article  Google Scholar 

  22. 22.

    Biggs TC, Baruah P, Mainwaring J, Harries PG, Salib RJ (2013) Treatment algorithm for oral anticoagulant and antiplatelet therapy in epistaxis patients. J Laryngol Otol 127:483–488

    CAS  Article  Google Scholar 

  23. 23.

    Bola S, Marsh R, Braggins S, Potter C, Hickey S (2016) Does the continuation of warfarin change management outcomes in epistaxis patients? J Laryngol Otol 130:256–260

    CAS  Article  Google Scholar 

  24. 24.

    Stadler RR, Kindler R, Holzmann D et al (2016) The long-term fate of epistaxis patients with exposure to antithrombotic medication. Eur Arch Otorhinolaryngol 273:2561–2567

    Article  Google Scholar 

  25. 25.

    Holmes DR Jr, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL (2009) Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 54:95–109

    CAS  Article  Google Scholar 

  26. 26.

    Paikin JS, Wright DS, Eikelboom JW (2011) Effectiveness and safety of combined antiplatelet and anticoagulant therapy: a critical review of the evidence from randomized controlled trials. Blood Rev 25:123–129

    CAS  Article  Google Scholar 

  27. 27.

    Schaffer JM, Arnaoutakis GJ, Allen JG et al (2011) Bleeding complications and blood product utilization with left ventricular assist device implantation. Ann Thorac Surg 91:740–747

    Article  Google Scholar 

  28. 28.

    Dassanayaka S, Slaughter MS, Bartoli CR (2013) Mechanistic pathway (s) of acquired von Willebrand syndrome with a continuous-flow ventricular assist device: in vitro findings. ASAIO J 59:123–129

    CAS  Article  Google Scholar 

  29. 29.

    Meyer AL, Malehsa D, Bara C et al (2010) Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail 3:675–681

    Article  Google Scholar 

  30. 30.

    Starke RD, Ferraro F, Paschalaki KE et al (2011) Endothelial von Willebrand factor regulates angiogenesis. Blood 117:1071–1080

    CAS  Article  Google Scholar 

  31. 31.

    Baghai M, Heilmann C, Beyersdorf F et al (2015) Platelet dysfunction and acquired von Willebrand syndrome in patients with left ventricular assist devices. Eur J Cardiothorac Surg 48:421–427

    Article  Google Scholar 

  32. 32.

    Wever-Pinzon O, Selzman CH, Drakos SG et al (2013) Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail 6:517–526

    CAS  Article  Google Scholar 

  33. 33.

    Bhat P, Nassif ME, Vader JM et al (2014) Epistaxis in patients with left ventricular assist devices - incidence, risk factors, and implications. J Heart Lung Transplant 33:256

    Article  Google Scholar 

  34. 34.

    Rudmik L, Smith TL (2012) Management of intractable spontaneous epistaxis. Am J Rhinol Allergy 26(1):55–60

    Article  Google Scholar 

  35. 35.

    Miller LW, Pagani FD, Russell SD et al (2007) Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 357:885–896

    CAS  Article  Google Scholar 

  36. 36.

    Kirklin JK, Naftel DC, Pagani FD et al (2014) Sixth INTERMACS annual report: a 10.000-patient database. J Heart Lung Transplant 33:555–564

    Article  Google Scholar 

  37. 37.

    Stulak JM, Lee D, Haft JW et al (2014) Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. J Heart Lung Transplant 33:60–64

    Article  Google Scholar 

  38. 38.

    Borel-Derlon A, Federici AB, Roussel-Robert V et al (2007) Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 5:1115–1124

    CAS  Article  Google Scholar 

  39. 39.

    Fischer Q, Huisse MG, Voiriot G et al (2015) Von Willebrand factor, a versatile player in gastrointestinal bleeding in left ventricular assist device recipients? Transfusion 55:51–54

    Article  Google Scholar 

  40. 40.

    Cushing M, Kawaguchi K, Friedman KD, Mark T (2012) Factor VIII/ von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease. Transfusion 52:1535–1541

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Wiley Editing Services for English language editing.

Funding

Any research fund did not support this study.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Omer Vural.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval:

This retrospective study was performed after approval of the Ethical Committee of the University Hospital (Baskent University Medical and Health Sciences Research Council and Ethics Committee, KA 19/90) and has been performed according to the ethical standards of the Helsinki Declaration.

Informed consent

This was a retrospective data analysis study and it did not need informed consent.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Koycu, A., Vural, O., Bahcecitapar, M. et al. Device-related epistaxis risk: continuous-flow left ventricular assist device-supported patients. Eur Arch Otorhinolaryngol (2020). https://doi.org/10.1007/s00405-020-06127-z

Download citation

Keywords

  • Epistaxis
  • Left ventricular assist device
  • Anticoagulant therapy
  • Antiaggregant therapy
  • Von Willebrand factor
  • Mitral valve replacement
  • Spontaneous nontraumatic epistaxis
  • Nonepistaxis bleeding
  • Septum
  • Hemorrhagic complications